Cover Image
Market Research Report

Peanut Allergy - Pipeline Review, H2 2018

Published by Global Markets Direct Product code 251569
Published Content info 117 Pages
Delivery time: 1-2 business days
Price
Back to Top
Peanut Allergy - Pipeline Review, H2 2018
Published: October 16, 2018 Content info: 117 Pages
Description

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peanut Allergy - Pipeline Review, H2 2018, provides an overview of the Peanut Allergy (Immunology) pipeline landscape.

Peanut allergy is common, especially in children. An allergic response to peanuts usually occurs within minutes after exposure, and symptoms range from mild to severe. Peanut allergy signs and symptoms can include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, digestive problems, such as diarrhea, stomach cramps, nausea or vomiting, tightening of the throat, shortness of breath or wheezing and runny nose.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peanut Allergy - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Peanut Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peanut Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Peanut Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 4, 5, 7, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 2 and 1 molecules, respectively.

Peanut Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Peanut Allergy (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Peanut Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Peanut Allergy (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Peanut Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Peanut Allergy (Immunology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Peanut Allergy (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Peanut Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC10905IDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Peanut Allergy - Overview
    • Peanut Allergy - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Peanut Allergy - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Peanut Allergy - Companies Involved in Therapeutics Development
    • Adverum Biotechnologies Inc
    • Aimmune Therapeutics Inc
    • Alfacyte Ltd
    • Allergy Therapeutics Plc
    • AnaptysBio Inc
    • ASIT Biotech SA
    • Astellas Pharma Inc
    • BioLingus AG
    • BlueWillow Biologics Inc
    • Cambridge Allergy Ltd
    • DBV Technologies SA
    • F. Hoffmann-La Roche Ltd
    • HAL Allergy BV
    • Inimmune Corp
    • Intrommune Therapeutics
    • Regeneron Pharmaceuticals Inc
    • Sanofi
  • Peanut Allergy - Drug Profiles
    • AK-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aldesleukin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ANN-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AR-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-0892 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CA-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DBV-712 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Inhibit CYP11A1 for Peanut Allergy and Asthma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dupilumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etokimab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HALMPE-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INT-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omalizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pnt-ASIT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Polyvac Peanut - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PVX-108 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-439794 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SCV-204 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to target TLR for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VTC-064 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Peanut Allergy - Dormant Projects
  • Peanut Allergy - Discontinued Products
  • Peanut Allergy - Product Development Milestones
    • Featured News & Press Releases
      • Sep 12, 2018: DBV Technologies announces positive DSMB review of Part A of phase III study in peanut-allergic toddlers
      • Sep 06, 2018: Intrommune Therapeutics completes Pre-IND meeting with FDA on INT301 for peanut allergy
      • Aug 07, 2018: Aimmune Therapeutics Announces CEO Jayson Dallas Will Present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 15th
      • Jul 26, 2018: DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer
      • Jun 11, 2018: Aimmune Therapeutics Appoints Dr. Jayson Dallas as CEO
      • May 30, 2018: Aimmune Therapeutics Announces New Pan-European Study Showing Significant Psychosocial Burden Associated With Peanut Allergy
      • May 29, 2018: DBV Technologies Shows Commitment to the Development of Treatments for Food Allergies at EAACI 2018
      • May 28, 2018: Aimmune Therapeutics Announces New Clinical Data on AR101 for Peanut Allergy at the 2018 EAACI Congress
      • May 16, 2018: DBV Technologies Announces Appointment of Michel de Rosen to its Board of Directors
      • May 15, 2018: Aimmune Therapeutics to Present Data on Peanut Allergy at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018
      • May 15, 2018: Intrommune Therapeutics Submits Pre-IND Meeting Request to the U.S. FDA for INT301, Its Peanut Allergy Oral Mucosal Immunotherapy Drug Candidate, During Food Allergy Awareness Week
      • May 08, 2018: DBV Technologies to Present New Clinical Data of Viaskin Peanut at the 2018 EAACI Meeting
      • Apr 24, 2018: Intrommune Therapeutics to Present at Eighth Annual BioNJ BioPartnering Conference
      • Mar 26, 2018: AnaptysBio Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline Adult Peanut Allergy Patients
      • Mar 04, 2018: Aimmune Therapeutics Presents Results From the Positive, Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy at AAAAI-WAO
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Peanut Allergy, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Peanut Allergy - Pipeline by Adverum Biotechnologies Inc, H2 2018
  • Peanut Allergy - Pipeline by Aimmune Therapeutics Inc, H2 2018
  • Peanut Allergy - Pipeline by Alfacyte Ltd, H2 2018
  • Peanut Allergy - Pipeline by Allergy Therapeutics Plc, H2 2018
  • Peanut Allergy - Pipeline by AnaptysBio Inc, H2 2018
  • Peanut Allergy - Pipeline by ASIT Biotech SA, H2 2018
  • Peanut Allergy - Pipeline by Astellas Pharma Inc, H2 2018
  • Peanut Allergy - Pipeline by BioLingus AG, H2 2018
  • Peanut Allergy - Pipeline by BlueWillow Biologics Inc, H2 2018
  • Peanut Allergy - Pipeline by Cambridge Allergy Ltd, H2 2018
  • Peanut Allergy - Pipeline by DBV Technologies SA, H2 2018
  • Peanut Allergy - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
  • Peanut Allergy - Pipeline by HAL Allergy BV, H2 2018
  • Peanut Allergy - Pipeline by Inimmune Corp, H2 2018
  • Peanut Allergy - Pipeline by Intrommune Therapeutics, H2 2018
  • Peanut Allergy - Pipeline by Regeneron Pharmaceuticals Inc, H2 2018
  • Peanut Allergy - Pipeline by Sanofi, H2 2018
  • Peanut Allergy - Dormant Projects, H2 2018
  • Peanut Allergy - Discontinued Products, H2 2018

List of Figures

  • Number of Products under Development for Peanut Allergy, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Targets, H2 2018
  • Number of Products by Stage and Targets, H2 2018
  • Number of Products by Mechanism of Actions, H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Molecule Types, H2 2018
  • Number of Products by Stage and Molecule Types, H2 2018
Back to Top